|
1
|
European Association for the Study of the
Liver. Electronic address simpleeasloffice@easloffice.eu;
European Association for the Study of the liver. EASL clinical
practice guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Llovet JM, Bustamante J, Castells A,
Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J and Bruix J: Natural
history of untreated nonsurgical hepatocellular carcinoma:
Rationale for the design and evaluation of therapeutic trials.
Hepatology. 29:62–67. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kudo M, Kitano M, Sakurai T and Nishida N:
General rules for the clinical and pathological study of primary
liver cancer, nationwide follow-up survey and clinical practice
guidelines: The outstanding achievements of the liver cancer study
group of Japan. Dig Dis. 33:765–770. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
National Cancer Institute (NCI): Common
Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017.
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.
Accessed May 18, 2020.
|
|
9
|
Kudo M: Combination cancer immunotherapy
with molecular targeted Agents/Anti-CTLA-4 antibody for
hepatocellular carcinoma. Liver Cancer. 8:1–11. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Golfieri R, Giampalma E, Renzulli M, Cioni
R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R,
Gasparini D, et al: Randomised controlled trial of
doxorubicin-eluting beads vs conventional chemoembolisation for
hepatocellular carcinoma. Br J Cancer. 111:255–264. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
van Malenstein H, Maleux G, Vandecaveye V,
Heye S, Laleman W, van Pelt J, Vaninbroukx J, Nevens F and Verslype
C: A randomized phase II study of drug-eluting beads versus
transarterial chemoembolization for unresectable hepatocellular
carcinoma. Onkologie. 34:368–376. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle
PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al:
Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased α-fetoprotein concentrations
(REACH-2): A randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 20:282–296. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Abou-Alfa GK, Meyer T, Cheng AL,
El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park
JW, et al: Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Koyama N, Saito K, Nishioka Y, Yusa W,
Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K and Tamura T:
Pharmacodynamic change in plasma angiogenic proteins: A
dose-escalation phase 1 study of the multi-kinase inhibitor
lenvatinib. BMC Cancer. 14(530)2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tohyama O, Matsui J, Kodama K, Hata-Sugi
N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y:
Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor
that targets multiple receptor tyrosine kinases in preclinical
human thyroid cancer models. J Thyroid Res.
2014(638747)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marin JJG, Macias RIR, Monte MJ, Romero
MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG,
Espinosa-Escudero R, Reviejo M, et al: Molecular Bases of Drug
Resistance in Hepatocellular Carcinoma. Cancers (Basel).
12(1663)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McGranahan N and Swanton C: Clonal
heterogeneity and tumor evolution: Past, present, and the future.
Cell. 168:613–628. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang Y and Weinberg RA:
Epithelial-to-mesenchymal transition in cancer: Complexity and
opportunities. Front Med. 12:361–373. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lee YS, Kim SM, Kim BW, Chang HJ, Kim SY,
Park CS, Park KC and Chang HS: Anti-cancer effects of HNHA and
lenvatinib by the suppression of EMT-mediated drug resistance in
cancer stem cells. Neoplasia. 20:197–206. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Saji M and Ringel MD: The PI3K-Akt-mTOR
pathway in initiation and progression of thyroid tumors. Mol Cell
Endocrinol. 321:20–28. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ghidini M, Petrelli F, Ghidini A,
Tomasello G, Hahne JC, Passalacqua R and Barni S: Clinical
development of mTor inhibitors for renal cancer. Expert Opin
Investig Drugs. 26:1229–1237. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hiraoka A, Kumada T, Kudo M, Hirooka M,
Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, et al:
Hepatic function during repeated TACE procedures and prognosis
after introducing sorafenib in patients with unresectable
hepatocellular carcinoma: Multicenter analysis. Dig Dis.
35:602–610. 2017.PubMed/NCBI View Article : Google Scholar
|
